Stock Code: 000028/200028 Notice No.: 2022-23Short Form of the Stock: Sinopharm Accord /Accord B
China National Accord Medicines Corporation Ltd.
The First Quarterly Report for 2022
Important content reminder:
1. Board of Directors, Supervisory Committee, all directors, supervisors and senior executives of China NationalAccord Medicines Corporation Ltd. (hereinafter referred to as the Company) hereby confirm that there are no anyfictitious statements, misleading statements, or important omissions carried in this report, and shall take allresponsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents.
2. Principal of the Company, Person in Charge of Accounting Works and Person in Charge of Accounting Organ(Accounting Officer) hereby confirm that the Financial Report of the First Quarterly Report is authentic, accurateand complete.
3. Whether the First Quarterly Report has been audited or not
□Yes √No
I. Main financial data(i) Main accounting data and financial indexesWhether it has retroactive adjustment or re-statement on previous accounting data or not
□Yes√ No
The Company and whole members of the BOD guarantee that the information disclosed is true,accurate and complete, and there are no any fictitious records, misleading statements or importantomissions.
| Current Period | Same period of last year | Changes of this period over same period of last year | |
| Operating income (RMB) | 17,150,856,946.54 | 16,049,966,325.75 | 6.86% |
| Net profit attributable to shareholders of the listed company (RMB) | 252,361,872.69 | 328,800,560.24 | -23.25% |
| Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses (RMB) | 242,244,636.06 | 321,593,612.98 | -24.67% |
| Net cash flow arising from operating activities (RMB) | -217,452,223.38 | -306,748,999.24 | 29.11% |
| Basic earnings per share (RMB/Share) | 0.59 | 0.77 | -23.38% |
| Diluted earnings per share (RMB/Share) | 0.59 | 0.77 | -23.38% |
| Weighted average ROE | 1.68% | 2.33% | 0.65 percentage points |
| down | |||
| End of this period | End of last period | Changes of this period-end over same period-end of last year | |
| Total assets (RMB) | 44,844,103,338.63 | 42,783,682,431.81 | 4.82% |
| Owners’ equity attributable to shareholders of listed company (RMB) | 15,177,183,542.81 | 14,924,938,052.50 | 1.69% |
Explanation on the business performance and financial status:
The Company achieved operation income of 17,151 million yuan for the first quarter of 2022, a year-on-year increase of 6.86%;operation profit was 375 million yuan, 20.42% down from a year earlier; the net profit attributable to shareholder of listed companywas 252 million yuan, decrease of 23.25% on a year-on-year basis, the basic EPS decreased by 23.38% correspondingly andweighted ROE decreased by 0.65 percentage points. Profit decline mainly due to the impact of COVID-19, the performance fromaffiliates declined and the investment earnings decreased accordingly. Meanwhile, the customer flow from retail segment drops dueto the epidemic, and the new stores operated in 2021 have a large initial investment, the benefits are not yet visible with shrinkingprofit space.The distribution segment has an operation income of 12,171 million yuan, a year-on-year growth of 7.45%; net profit was 210million yuan, a year-on-year increase of 10.40%. the retail segment has 5,238 million yuan from the operation income, a year-on-yearincrease of 5.11% and achieved a net profit of 32 million yuan, down 63.80% on a year-on-year basis.(ii) Items of non-recurring gains and losses
√ Applicable □ Not applicable
Unit: RMB/CNY
| Item | Current amount | Note |
| Gains/losses from the disposal of non-current asset (including the write-off that accrued for impairment of assets) | 785,738.83 | The gains on disposal of right-to-use asses arising from off-lease in the period |
| Governmental subsidy calculated into current gains and losses(while closely related with the normal business of the Company, the government subsidy that accord with the provision of national policies and are continuously enjoyed in line with a certain standard quota or quantity are excluded) | 15,562,891.34 | Mainly the various special subsidies and tax rebates received in the Period |
| Reversal of the account receivable depreciation reserves subject to separate impairment test | 1,632,768.34 | |
| Other non-operating income and expenses other than the above | 1,205,854.08 | |
| Other gains/losses items that meet the definition of non-recurring gains/losses | 1,789,818.44 | |
| Less: impact on income tax | 5,104,445.81 | |
| Impact on minority shareholders’ equity (post-tax) | 5,755,388.59 | |
| Total | 10,117,236.63 | -- |
Details of other gains/losses items that meet the definition of non-recurring gains/losses:
□ Applicable √ Not applicable
There are no other gains/losses items that meet the definition of non-recurring gains/losses in the Company.Explain the items defined as recurring profit (gain)/loss according to the lists of extraordinary profit (gain)/loss in Q&AAnnouncement No.1 on Information Disclosure for Companies Offering Their Securities to the Public --- Extraordinary Profit/loss
□ Applicable √ Not applicable
There are no items defined as recurring profit (gain)/loss according to the lists of extraordinary profit (gain)/loss in Q&AAnnouncement No.1 on Information Disclosure for Companies Offering Their Securities to the Public --- Extraordinary Profit/loss(iii) Particulars about material changes in items of main accounting statement and financial index and explanations ofreasons
√ Applicable □Not applicable
(1)Receivable financing: decrease of 557.8708 million yuan from beginning of the Period with a growth rate of -54.31%, mainly dueto the increase in discounting of bank acceptance in the Period;
(2) Construction in progress: decrease of 15.0976 million yuan from beginning of the Period with a growth rate of -30.29%, mainlybecause the ERP project transfer-out after completion & acceptance;
(3) Short-term borrowings: increase of 1,108.1141 million yuan from beginning of the Period with a growth rate of 57.40%, mainlydue to the increase in financing with the invoice of account payable;
(4) Employee benefits payable: decrease of 114.3872 million yuan from beginning of the Period with a growth rate of -33.62%,mainly because the wages and bonuses accrued in the prior year are paid in the Period;
(5) Other incomes: a year-on-year increase of 11.3852 million yuan with a growth rate of 83.37%, mainly because various subsidiesreceived in the Period and the tax relief increased on a year-on-year basis;
(6) Investment income: a year-on-year decrease of 67.8440 million yuan with a growth rate of -74.30%, mainly because theperformance from affiliates declined and the investment earnings decreased accordingly;
(7) Credit impairment losses: a year-on-year increase of 8.7011 million yuan with a growth rate of 50.60%, mainly due to theincrease of account receivable at period-end compared to the same period of last year for the sales up; affected by the epidemic,medical insurance allocation was delayed, the capital operation from hospital are relatively tight which had a certain impact on thereceivable collection of the Company, turnover days of the receivable increase to some extent, than the bad debt provision goes upcorrespondingly;
(8) Impairment losses: a year-on-year decrease of 1.8342 million yuan with a growth rate of -52.58%, mainly due to the decrease inprovision for inventory falling price reserves on a year-on-year basis;
(9) Gain on disposal of assets: a year-on-year increase of 0.7065 million yuan with a growth rate of 259.86%, mainly due to theincrease in earnings on a year-on-year basis, resulting from disposal of the right-of-use assets for vacating from retail stores.
(10)Non-operating income: a year-on-year decrease of 4.0821 million yuan with a growth rate of -64.08%, mainly because in thePeriod, the payable without payment requirements written off declined from a year earlier;
(11) Non-controlling interests: a year-on-year decrease of 18.3534 million yuan with a growth rate of -30.20%, mainly because thenet profit attributable to owners of parent company from subsidiary-Sinopharm Holding Guoda Drugstore Co., Ltd.(hereinafterreferred to as Guoda Drugstore) declined on a year-on-year basis, accordingly, the gains/losses of minority attributable to thestrategic investor of the Group-Walgreens Boots Alliance(Hong Kong)Investments Limited (hereinafter referred to as WBA)decreased on a year-on-year basis;
(12) Total comprehensive income attributable to non-controlling interests: a year-on-year decrease of 18.3534 million yuan with agrowth rate of -30.20%, mainly because the net profit attributable to owners of parent company from subsidiary-Guoda Drugstoredeclined on a year-on-year basis, accordingly, the gains/losses of minority attributable to the strategic investor of the Group- WBAdecreased on a year-on-year basis;
(13) Receipts of taxes and surcharges refunds: a year-on-year decrease of 4.7192 million yuan with a growth rate of -84.00%, mainly
due to the year-on-year decline in enterprise income tax refunds received in the Period;
(14) Other cash receipts relating to operating activities: a year-on-year decrease of 64.1937 million yuan with a growth rate of-30.61%, mainly because the reserve funds for epidemic-specific, deposits and security deposit received in the Period declined from ayear earlier;
(15) Cash receipts from returns of investments: a year-on-year decrease of 2.9974 million yuan with a growth rate of -100.00%,mainly because in same period of last year, received the withdrawal payment from part of the projects of Sinopharm ZhongjinMedical Industry Fund, and there was no such matter occurred in the Period;
(16) Cash received from investment income: a year-on-year decrease of 3.5996 million yuan with a growth rate of -100.00%, mainlybecause in same period of last year, received dividend payment from projects of Sinopharm Zhongjin Medical Industry Fund, andthere was no such matter occurred in the Period;
(17) Net cash receipts from disposal of fixed assets, intangible assets and other long-term assets: a year-on-year decrease of 0.2423million yuan with a growth rate of -74.08%, mainly because the cash received in the Period from fixed assets disposal decreasedfrom a year earlier;
(18) Total cash inflows from investing activities: a year-on-year decrease of 6.8393 million yuan with a growth rate of -98.78%,mainly because in same period of last year, received dividend payment and withdrawal payment from projects of SinopharmZhongjin Medical Industry Fund, and there were no such matters occurred in the Period;
(19) Cash payments for investments: a year-on-year decrease of 8.7574 million yuan with a growth rate of -32.34%, mainly becausethe payment for rental transfer fees in the Period declined from a year earlier, paid by subsidiary - Guoda Drugstore;
(20) Net cash payments for acquisition of subsidiaries and other business units: a year-on-year decrease of 73.1595 million yuan witha growth rate of -100.00%, mainly because in same period of last year, subsidiary Guoda Drugstore paid for the acquisition of asubsidiary, and there was no such matter occurred in the Period;
(21) Total cash outflows from investing activities: a year-on-year decrease of 67.8542 million yuan with a growth rate of -41.83%,mainly because in same period of last year, subsidiary Guoda Drugstore paid for the acquisition of a subsidiary, and there was nosuch matter occurred in the Period;
(22) Net cash flows from investing activities: a year-on-year increase of 61.0148 million yuan with a growth rate of 39.29%, mainlybecause in same period of last year, subsidiary Guoda Drugstore paid for the acquisition of a subsidiary, and there was no such matteroccurred in the Period;
(23) Cash proceeds from investments by others: a year-on-year decrease of 4.98 million yuan with a growth rate of -84.69%, mainlydue to the year-on-year decrease in investment received from minority during the Period;
(24) Other cash receipts relating to financing activities: a year-on-year decrease of 192.0255 million yuan with a growth rate of-64.56%, mainly because in the Period, the recovery of factoring business and repayment difference declined on a year-on-year basis;
(25) Cash repayments for debts: a year-on-year increase of 94.2452 million yuan with a growth rate of 53.17%, mainly due to theincrease in repayment of loans due in the Period;
(26) Total cash outflows from financing activities: a year-on-year increase of 161.1150 million yuan with a growth rate of 33.41%,mainly because repayment of loans from financial institutions and the rents paid for increasing retail stores in the Period increased ona year-on-year basis;
(27) Net cash flows from financing activities: a year-on-year decrease of 276.5162 million yuan with a growth rate of -71.17%,mainly because in the Period, the recovery of factoring business and repayment difference declined on a year-on-year basis, the rentspaid for increasing retail stores in the Period increased on a year-on-year basis;
(28) Effect of foreign exchange rate changes on cash and cash equivalents: a year-on-year increase of 1,989.89 yuan with a growthrate of 81.53%, mainly due to the change of exchange rates;
(29) Net increase of cash and cash equivalents :a year-on-year decrease of 126.2026 million yuan with a growth rate of -171.70%,mainly because in the Period, the recovery of factoring business and repayment difference declined on a year-on-year basis, the rentspaid for increasing retail stores in the Period increased on a year-on-year basis.
II. Shareholders(i) Total number of common shareholders and preference shareholders with voting rights recovered andtop ten shareholders
Unit: Share
| Total number of common shareholders at the end of report period | 44,112 | Total preference shareholders with voting rights recovered at end of reporting period (if applicable) | 0 | |||||
| Top ten shareholders | ||||||||
| Shareholder’s name | Nature of shareholder | Proportion of shares held | Amount of shares held | Amount of lock-up shares held | Information of shares pledged, tagged or frozen | |||
| State of share | Amount | |||||||
| Sinopharm Group Co., Ltd. | State-owned Corporation | 56.06% | 239,999,991 | 5,505,770 | ||||
| FIRST SENTIER INVESTORS GLOBAL UMBRELLA FUND PLC - FSSA CHINA GROWTH FUND | Foreign Corporation | 2.52% | 10,802,495 | |||||
| Hong Kong Securities Clearing Company Ltd. | Foreign Corporation | 2.28% | 9,751,340 | |||||
| China National Pharmaceutical Foreign Trade Corp. | State-owned Corporation | 1.24% | 5,323,043 | |||||
| National Social Security Fund 413 Portfolio | Domestic non state-owned Corporation | 1.07% | 4,590,032 | |||||
| BBH BOS S/A FIDELITY FD - CHINA FOCUS FD | Foreign Corporation | 0.78% | 3,358,761 | |||||
| Fidelity Investment Management | Foreign Corporation | 0.54% | 2,301,737 | |||||
| (Hong Kong) Limited - Client’s fund | ||||||
| ICBC-Guolian Andesheng Small Selected Securities Investment Fund | Domestic non state-owned Corporation | 0.38% | 1,632,000 | |||
| CPIC Fund -China Pacific Life Insurance Co., Ltd. - with-profit insurance- CPIC Fund China Pacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan | Domestic non state-owned Corporation | 0.34% | 1,470,224 | |||
| VANGUARD EMERGING MARKETS STOCK INDEX FUND | Foreign Corporation | 0.34% | 1,456,150 | |||
| Top ten shareholders with unrestricted shares held | ||||||
| Shareholder’s name | Amount of unrestricted shares held | Type of shares | ||||
| Type | Amount | |||||
| Sinopharm Group Co., Ltd. | 234,494,221 | RMB ordinary shares | 234,494,221 | |||
| FIRST SENTIER INVESTORS GLOBAL UMBRELLA FUND PLC - FSSA CHINA GROWTH FUND | 10,802,495 | Domestically listed foreign shares | 10,802,495 | |||
| Hong Kong Securities Clearing Company Ltd. | 9,751,340 | RMB ordinary shares | 9,751,340 | |||
| China National Pharmaceutical Foreign Trade Corp. | 5,323,043 | RMB ordinary shares | 5,323,043 | |||
| National Social Security Fund 413 Portfolio | 4,590,032 | RMB ordinary shares | 4,590,032 | |||
| BBH BOS S/A FIDELITY FD - CHINA FOCUS FD | 3,358,761 | Domestically listed foreign shares | 3,358,761 |
| Fidelity Investment Management (Hong Kong) Limited - Client’s fund | 2,301,737 | RMB ordinary shares | 2,301,737 |
| ICBC-Guolian Andesheng Small Selected Securities Investment Fund | 1,632,000 | RMB ordinary shares | 1,632,000 |
| CPIC Fund -China Pacific Life Insurance Co., Ltd. - with-profit insurance- CPIC Fund China Pacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan | 1,470,224 | RMB ordinary shares | 1,470,224 |
| VANGUARD EMERGING MARKETS STOCK INDEX FUND | 1,456,150 | Domestically listed foreign shares | 1,456,150 |
| Explanation on associated relationship among the aforesaid shareholders | Sinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade Corporation have the same actual controller, which is China National Pharmaceutical Group Corporation. It is unknown that there exists no associated relationship or belongs to the consistent actionist among the other tradable shareholders regulated by the Management Measure of Information Disclosure on Change of Shareholding for Listed Companies. | ||
(ii) Total shareholders with preferred stock held and shares held by top ten shareholders with preferredstock held
□ Applicable √ Not applicable
III. Other important matters
□ Applicable √ Not applicable
IV. Quarterly financial statements(i) Financial statement
1. Consolidate Balance Sheet
Prepared by China National Accord Medicines Corporation Ltd.
March 31, 2022
Unit: RMB/CNY
| Item | Ending balance | Opening balance |
| Current assets: | ||
| Cash and bank balances | 4,867,544,893.18 | 5,126,159,080.94 |
| Settlement provisions | ||
| Capital lent | ||
| Trading financial assets |
| Derivative financial assets | ||
| Notes receivable | 642,430,566.93 | 680,196,380.57 |
| Accounts receivable | 18,445,260,411.58 | 15,964,603,345.91 |
| Receivable financing | 469,356,116.33 | 1,027,226,940.21 |
| Advances to suppliers | 477,599,161.72 | 520,930,545.31 |
| Insurance receivable | ||
| Reinsurance receivables | ||
| Contract reserve of reinsurance receivable | ||
| Other receivables | 654,794,241.77 | 718,089,129.10 |
| Including: Interest receivable | ||
| Dividend receivable | ||
| Buying back the sale of financial assets | ||
| Inventories | 8,058,564,605.96 | 7,621,541,595.08 |
| Contract assets | 29,728,855.46 | 29,061,159.52 |
| Assets held for sale | ||
| Non-current asset due within one year | ||
| Other current assets | 140,830,256.92 | 160,607,355.66 |
| Total current assets | 33,786,109,109.85 | 31,848,415,532.30 |
| Non-current assets: | ||
| Loans and payments on behalf | ||
| Debt investment | ||
| Other debt investment | ||
| Long-term account receivable | ||
| Long-term equity investments | 2,501,295,548.16 | 2,459,832,546.74 |
| Other equity instruments investment | 62,488,312.99 | 62,488,312.99 |
| Other non-current financial assets | 135,974,908.51 | 135,974,908.51 |
| Investment properties | 112,808,525.33 | 113,981,497.23 |
| Fixed assets | 850,200,561.56 | 868,626,258.43 |
| Construction in progress | 34,751,943.39 | 49,849,506.70 |
| Productive biological asset | ||
| Oil and gas asset | ||
| Right-of-use assets | 2,664,487,497.37 | 2,575,240,340.00 |
| Intangible assets | 678,354,661.52 | 669,926,562.82 |
| Expense on Research and Development | ||
| Goodwill | 2,775,645,585.32 | 2,775,645,585.32 |
| Long-term prepaid expenses | 621,061,288.02 | 633,975,441.76 |
| Deferred tax assets | 154,699,087.40 | 129,740,169.77 |
| Other non-current assets | 466,226,309.21 | 459,985,769.24 |
| Total non-current assets t | 11,057,994,228.78 | 10,935,266,899.51 |
| Total assets | 44,844,103,338.63 | 42,783,682,431.81 |
| Current liabilities: | ||
| Short-term borrowings | 3,038,581,281.11 | 1,930,467,146.38 |
| Loan from central bank | ||
| Capital borrowed | ||
| Trading financial liability | ||
| Derivative financial liability |
| Notes payable | 6,759,000,854.12 | 7,660,216,823.68 |
| Accounts payable | 10,610,876,048.40 | 9,057,718,968.14 |
| Receipts in advance | 18,591,112.89 | 19,289,567.44 |
| Contract liabilities | 429,473,280.23 | 431,303,231.37 |
| Selling financial asset of repurchase | ||
| Absorbing deposit and interbank deposit | ||
| Security trading of agency | ||
| Security sales of agency | ||
| Employee benefits payable | 225,809,878.05 | 340,197,125.33 |
| Tax payable | 307,116,334.60 | 337,164,080.19 |
| Other payables | 1,907,708,455.77 | 1,714,746,986.46 |
| Including: Interest payable | 37,765,231.34 | 31,587,062.03 |
| Dividend payable | 30,140,616.33 | 30,140,616.33 |
| Commission charge and commission payable | ||
| Reinsurance payable | ||
| Liability held for sale | ||
| Non-current liabilities due within one year | 851,459,913.02 | 848,328,648.14 |
| Other current liabilities | 37,309,563.28 | 39,585,469.65 |
| Total current liabilities | 24,185,926,721.47 | 22,379,018,046.78 |
| Non-current liabilities: | ||
| Insurance contract reserve | ||
| Long-term borrowings | 70,137,173.89 | 71,637,173.89 |
| Bonds payable | ||
| Including: Preferred stock | ||
| Perpetual capital securities | ||
| Lease liabilities | 1,420,668,973.13 | 1,375,427,877.28 |
| Long-term payables | 6,938,189.00 | 6,938,189.00 |
| Long-term employee benefits payable | 1,202,000.00 | 1,202,000.00 |
| Provisions | ||
| Deferred income | 85,016,983.16 | 86,917,051.78 |
| Deferred tax liabilities | 172,433,335.41 | 175,948,328.93 |
| Other non-current liabilities | 584,974,923.18 | 664,381,065.65 |
| Total non-current liabilities | 2,341,371,577.77 | 2,382,451,686.53 |
| Total liabilities | 26,527,298,299.24 | 24,761,469,733.31 |
| Equity | ||
| Share capital | 428,126,983.00 | 428,126,983.00 |
| Other equity instrument | ||
| Including: Preferred stock | ||
| Perpetual capital securities | ||
| Capital surplus | 4,371,621,053.65 | 4,371,802,107.43 |
| Less: Inventory shares | ||
| Other comprehensive income | 21,938,869.76 | 21,874,198.36 |
| Reasonable reserve | ||
| Surplus reserve | 214,063,491.50 | 214,063,491.50 |
| Provision of general risk | ||
| Retained earnings | 10,141,433,144.90 | 9,889,071,272.21 |
| Total equity attributable to owners of the parent | 15,177,183,542.81 | 14,924,938,052.50 |
| Non-controlling interests | 3,139,621,496.58 | 3,097,274,646.00 |
| Total equity | 18,316,805,039.39 | 18,022,212,698.50 |
| Total liabilities and equity | 44,844,103,338.63 | 42,783,682,431.81 |
Legal Representative: Lin ZhaoxiongPerson in charge of accounting works: Gu GuolinPerson in charge of accounting institute: Wang Ying
2. Consolidated Profit Statement
Unit: RMB/CNY
| Item | Current period | Last period |
| I. Total operating income | 17,150,856,946.54 | 16,049,966,325.75 |
| Including: Operating revenue | 17,150,856,946.54 | 16,049,966,325.75 |
| Interest income | ||
| Insurance gained | ||
| Commission charge and commission income | ||
| II. Total operating cost | 16,797,706,856.47 | 15,663,170,079.60 |
| Including: Operating costs | 15,227,900,206.53 | 14,260,591,404.46 |
| Interest expense | ||
| Commission charge and commission expense | ||
| Cash surrender value | ||
| Net amount of expense of compensation | ||
| Net amount of withdrawal of insurance contract reserve | ||
| Bonus expense of guarantee slip | ||
| Reinsurance expense | ||
| Tax and surcharges | 41,939,571.15 | 33,744,327.20 |
| Selling expenses | 1,203,497,011.57 | 1,080,543,941.75 |
| Administrative expenses | 264,532,679.98 | 237,615,927.36 |
| R&D expense | ||
| Finance costs | 59,837,387.24 | 50,674,478.83 |
| Including: Interest expenses | 72,514,879.45 | 68,683,688.49 |
| Interest income | 16,770,723.32 | 18,058,735.03 |
| Add: other incomes | 25,040,832.98 | 13,655,624.72 |
| Investment income (Loss is listed with “-”) | 23,461,476.68 | 91,305,476.74 |
| Including: Investment income from associates | 41,579,383.80 | 92,441,826.44 |
| Income from the derecognition of financial assets measured at amortised cost (Loss is listed with “-”) | -18,117,907.12 | -4,735,905.31 |
| Exchange income (Loss is listed with “-”) |
| Net exposure hedging income (Loss is listed with “-”) | ||
| Income from change of fair value (Loss is listed with “-”) | ||
| Credit impairment losses/ (Loss is listed with “-”) | -25,898,207.09 | -17,197,080.80 |
| Impairment losses (Loss is listed with “-”) | -1,654,289.70 | -3,488,500.85 |
| Gain on disposal of assets (Loss is listed with “-”) | 978,407.63 | 271,889.26 |
| III. Operating profits (Loss is listed with “-”) | 375,078,310.57 | 471,343,655.22 |
| Add: Non-operating income | 2,288,693.57 | 6,370,834.89 |
| Less: Non-operatingexpenses | 600,906.15 | 570,737.09 |
| IV. Total profit (Loss is listed with “-”) | 376,766,097.99 | 477,143,753.02 |
| Less: Income tax expenses | 81,994,493.36 | 87,580,022.00 |
| V. Net profit (Net loss is listed with “-”) | 294,771,604.63 | 389,563,731.02 |
| (i) Classify by business continuity | ||
| 1. Profit or loss from continuing operations (net loss listed with ‘-”) | 294,771,604.63 | 389,563,731.02 |
| 2.termination of net profit (net loss listed with ‘-”) | ||
| (ii) Classify by ownership | ||
| 1. Owners of the parent | 252,361,872.69 | 328,800,560.24 |
| 2. Non-controlling interests | 42,409,731.94 | 60,763,170.78 |
| VI. Other comprehensive income, net of tax | 64,671.40 | 84,503.76 |
| Other comprehensive income, net of tax, attributable to owners of the parent | 64,671.40 | 84,503.76 |
| (i) Other comprehensive income items which will not be reclassified subsequently to profit of loss | ||
| 1.Changes of the defined benefit plans that re-measured | ||
| 2.Other comprehensive income under equity method that cannot be transfer to gain/loss | ||
| 3.Change of fair value of investment in other equity instrument | ||
| 4.Fair value change of enterprise's credit risk | ||
| 5. Other | ||
| (ii) Other comprehensive income that will be reclassified to profit or loss | 64,671.40 | 84,503.76 |
| 1. Other comprehensive income using the equity method that may be reclassified to profit or loss | 64,671.40 | 84,503.76 |
| 2.Change of fair value of other debt investment | ||
| 3.Amount of financial assets re-classify to other comprehensive income | ||
| 4.Credit impairment provision for other debt investment | ||
| 5.Cash flow hedging reserve | ||
| 6.Translation differences arising on |
| translation of foreign currency financial statements | ||
| 7.Other | ||
| Net after-tax of other comprehensive income attributable to minority shareholders | ||
| VII. Total comprehensive income | 294,836,276.03 | 389,648,234.78 |
| Total comprehensive income attributable to owners of the parent | 252,426,544.09 | 328,885,064.00 |
| Total comprehensive income attributable to non-controlling interests | 42,409,731.94 | 60,763,170.78 |
| VIII. Earnings per share: | ||
| (i) Basic earnings per share | 0.59 | 0.77 |
| (ii) Diluted earnings per share | 0.59 | 0.77 |
Enterprise combine under the same control in the Period, the combined party realized net profit of 0.00 Yuan before combination, andrealized 0.00 Yuan at last period for combined party.Legal Representative: Lin ZhaoxiongPerson in charge of accounting works: Gu GuolinPerson in charge of accounting institute: Wang Ying
3. Consolidated Cash Flow Statement
Unit: RMB/CNY
| Item | Current period | Last period |
| I. Cash flows from operating activities: | ||
| Cash received from sales of good or rendering of services | 16,757,405,030.62 | 15,194,724,502.12 |
| Net increase of customer deposit and interbank deposit | ||
| Net increase of loan from central bank | ||
| Net increase of capital borrowed from other financial institution | ||
| Cash received from original insurance contract fee | ||
| Net cash received from reinsurance business | ||
| Net increase of insured savings and investment | ||
| Cash received from interest, commission charge and commission | ||
| Net increase of capital borrowed | ||
| Net increase of returned business capital | ||
| Net cash received by agents in sale and purchase of securities | ||
| Receipts of taxes and surcharges refunds | 898,760.75 | 5,617,976.11 |
| Other cash receipts relating to operating activities | 145,551,765.30 | 209,745,502.46 |
| Total cash inflows from operating activities | 16,903,855,556.67 | 15,410,087,980.69 |
| Cash payments for goods and services | 15,413,374,469.33 | 14,094,028,880.65 |
| Net increase of customer loans and advances | ||
| Net increase of deposits in central bank and interbank |
| Cash paid for original insurance contract compensation | ||
| Net increase of capital lent | ||
| Cash paid for interest, commission charge and commission | ||
| Cash paid for bonus of guarantee slip | ||
| Cash payments to and on behalf of employees | 999,525,639.18 | 894,497,321.19 |
| Payments of all types of taxes and surcharges | 416,425,915.99 | 354,054,737.85 |
| Other cash payments relating to operating activities | 291,981,755.55 | 374,256,040.24 |
| Total cash outflows from operating activities | 17,121,307,780.05 | 15,716,836,979.93 |
| Net cash flows from operating activities | -217,452,223.38 | -306,748,999.24 |
| II. Cash flows from investing activities: | ||
| Cash receipts from returns of investments | 2,997,441.73 | |
| Cash received from investment income | 3,599,555.61 | |
| Net cash receipts from disposal of fixed assets, intangible assets and other long-term assets | 84,789.95 | 327,119.50 |
| Net cash received from disposal of subsidiaries and other units | ||
| Other cash receipts relating to investing activities | ||
| Total cash inflows from investing activities | 84,789.95 | 6,924,116.84 |
| Cash payments to acquire fixed assets, intangible assets and other long-term assets | 76,023,361.87 | 61,960,648.98 |
| Cash payments for investments | 18,322,350.00 | 27,079,733.00 |
| Net increase of mortgaged loans | ||
| Net cash payments for acquisition of subsidiaries and other business units | 73,159,498.29 | |
| Cash payments related to other investing activities | ||
| Total cash outflows from investing activities | 94,345,711.87 | 162,199,880.27 |
| Net cash flows from investing activities | -94,260,921.92 | -155,275,763.43 |
| III. Cash flows from financing activities | ||
| Cash proceeds from investments by others | 900,000.00 | 5,880,000.00 |
| Incl: Cash receipts from capital contributions from non-controlling interests of subsidiaries | 900,000.00 | 5,880,000.00 |
| Cash receipts from borrowings | 649,000,000.00 | 567,395,696.23 |
| Other cash receipts relating to financing activities | 105,391,223.35 | 297,416,755.19 |
| Total cash inflows from financing activities | 755,291,223.35 | 870,692,451.42 |
| Cash repayments for debts | 271,500,000.00 | 177,254,802.73 |
| Cash payments for distribution of dividends or profit and interest expenses | 63,873,455.61 | 59,139,307.66 |
| Incl: Dividends or profit paid to non-controlling shareholders of subsidiaries | 962,881.36 | 555,825.80 |
| Other cash payments relating to financing activities | 307,909,948.17 | 245,774,326.14 |
| Total cash outflows from financing activities | 643,283,403.78 | 482,168,436.53 |
| Net cash flows from financing activities | 112,007,819.57 | 388,524,014.89 |
| IV. Effect of foreign exchange rate changes on cash and cash equivalents | -450.89 | -2,440.78 |
| V. Net increase of cash and cash equivalents | -199,705,776.62 | -73,503,188.56 |
| Add: Cash and cash equivalents at beginning of the year | 4,733,512,172.37 | 5,405,113,257.99 |
| VI. Cash and cash equivalents at end of year | 4,533,806,395.75 | 5,331,610,069.43 |
(ii) Audit report
Whether the 1
stquarterly report has been audited or not
□Yes √ No
The 1stquarterly report of the Company has not been audited.
China National Accord Medicines Corporation Ltd.
Legal representative: Lin Zhaoxiong
April 28, 2022